Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | PTEN negative |
| Therapy | Abiraterone + Capivasertib |
| Indication/Tumor Type | prostate cancer |
| Response Type | sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| PTEN negative | prostate cancer | sensitive | Abiraterone + Capivasertib | Guideline | Actionable | Zytiga (abiraterone) plus Truqap (capivasertib) in combination with androgen deprivation therapy (category 2B) is included in guidelines for select patients with PTEN-deficient (defined as >= 90%) castration-sensitive prostate cancer (NCCN.org). | detail... |
| PubMed Id | Reference Title | Details |
|---|---|---|
| NCCN.org | Full reference... |